Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Sep 18, 2020 1:35 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 11, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Sep. 11, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that on September 10, 2020 ,

Mirum Pharmaceuticals to Present at Investor Conferences in September

September 11, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Sep. 11, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that the company will present at the following virtual

Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access Program

September 1, 2020

- Maralixibat would be the first treatment available for use in Alagille syndrome, if approved - Completion of the NDA submission expected in the first quarter of 2021 - Expanded Access Program for maralixibat now open FOSTER CITY, Calif. --(BUSINESS WIRE)--Sep.

Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients With PFIC2 at Digital International Liver Congress 2020

August 29, 2020

Maralixibat demonstrates significant transplant-free survival for patients with progressive familial intrahepatic cholestasis (PFIC2) who achieved serum bile acid (sBA) control in five-year analysis (p=0.0006). sBA responders remain on maralixibat for more than five years with improvements across

Events

Cantor Fitzgerald Virtual Global Healthcare Conference

Sep 17, 2020 at 9:20 AM EDT

H.C. Wainwright & Co. 22nd Annual Global Investment Conference

Sep 14, 2020 at 9:30 AM EDT

EASL International Liver Congress 2020

Aug 27 - Aug 29, 2020

Investor Relations

Investor Relations

Corporate Profile

Header Menu